Triamcinolone Acetonide
Catalog No.S1628
Molecular Weight(MW): 434.5
Triamcinolone acetonide is a synthetic glucocorticoid, used in the symptomatic treatment of inflammation.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
Biological Activity
| Description | Triamcinolone acetonide is a synthetic glucocorticoid, used in the symptomatic treatment of inflammation. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Triamcinolone Acetonide significantly decreases the paracellular permeability of ECV304 cells and down-regulated ICAM-1 expression, consistent with immunocytochemical observations. [1] Triamcinolone reverses the osmotic swelling of glial cells in retinas of the rat that is observed under various experimental conditions: in retinas isolated at 3 days after transient retinal ischemia, in retinas of eyes with lipopolysaccharide-induced ocular inflammation, and in control retinas in the presence of Ba2+ (1 mM), H2O2 (200 mM), arachidonic acid (10 mM), or prostaglandin E2 (30 nM). [2] Triamcinolone Acetonide reduces GAG synthesis compared to control and IL-1 alone. Triamcinolone Acetonide increases GAG degradation. Triamcinolone Acetonide increases media GAG content compared to control and IL-1 explants. [3] |
|
| In vivo | Triamcinolone Acetonide (TAC), a synthetic glucocorticoid, induces cleft palate resulting from poor development of palatal shelves in mice. Triamcinolone Acetonide inhibits the proliferation of mesenchymal cells and affects the differentiation of MEE cells into stratified squamous epithelia in the palatal shelves of rat embryos. [4] Triamcinolone Acetonide reduces lameness, edema, and concentration of synovial fluid protein after the second LPS injection in horse. Triamcinolone Acetonide also induces higher WBC counts and mepivacaine concentrations in synovial fluid, compared with results for Mepivacaine alone. [5] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 87 mg/mL (200.23 mM) |
|---|---|---|
| Ethanol | 13 mg/mL (29.91 mM) | |
| Water | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 434.5 |
|---|---|
| Formula | C24H31FO6 |
| CAS No. | 76-25-5 |
| Storage | powder |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00105404 | Completed | Diabetic Retinopathy|Diabetic Macular Edema|DME | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) | March 9, 2005 | Phase 3 |
| NCT00100009 | Completed | Macular Degeneration | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) | December 9, 2004 | Phase 3 |
| NCT00101764 | Completed | Macular Degeneration|Retinal Vein Occlusion|Diabetic Retinopathy | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) | January 5, 2005 | Phase 1 |
| NCT02806752 | Recruiting | Wet Macular Degeneration | Aier School of Ophthalmology, Central South University | January 2017 | Phase 4 |
| NCT03002974 | Recruiting | Acute Gouty Arthritis | Swedish Orphan Biovitrum | December 2016 | Phase 2 |
| NCT02939482 | Recruiting | Spinal Stenosis|Lumbosacral Spondylosis|Radiculopathy | Navamindradhiraj University | October 2016 | -- |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
